Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma

[Reuters - UK Focus] – The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co’s application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, . . . → Read More: Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Similar Articles: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces Retirement of Brian Daniels